Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the target of a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 3,960,000 shares, a decrease of 5.3% from the May 15th total of 4,180,000 shares. Based on an average daily volume of 927,200 shares, the short-interest ratio is currently 4.3 days. Currently, 9.1% of the shares of the company are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ATXS. RA Capital Management L.P. acquired a new position in Astria Therapeutics during the 1st quarter worth $62,115,000. Perceptive Advisors LLC boosted its position in shares of Astria Therapeutics by 82.9% during the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after acquiring an additional 1,814,608 shares in the last quarter. Armistice Capital LLC acquired a new position in shares of Astria Therapeutics during the 4th quarter worth about $12,119,000. Artal Group S.A. acquired a new position in shares of Astria Therapeutics during the 1st quarter worth about $12,445,000. Finally, Vivo Capital LLC boosted its position in shares of Astria Therapeutics by 47.7% during the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock worth $19,067,000 after acquiring an additional 801,528 shares in the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Friday, May 10th. Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a report on Friday, May 10th. Oppenheimer lowered their target price on Astria Therapeutics from $29.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 21st. Finally, Jefferies Financial Group raised their target price on Astria Therapeutics from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 25th.

Astria Therapeutics Trading Down 3.5 %

Shares of Astria Therapeutics stock opened at $8.83 on Tuesday. Astria Therapeutics has a one year low of $4.26 and a one year high of $16.90. The business’s 50 day moving average price is $9.57 and its 200 day moving average price is $10.44.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). Analysts forecast that Astria Therapeutics will post -1.56 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.